End-To-End, Fully Automated Manufacturing of Hematopoietic Stem and Progenitor Cell Therapy Via CCR5-Targeted Integration
Abstract
Gene therapies utilizing hematopoietic stem and progenitor cells (HSPCs) have curative potential across hematologic diseases, but manual manufacturing workflows are costly and difficult to scale, limiting patient access. Here, we demonstrated automation of an HSPC gene knock-in protocol on a high-throughput manufacturing platform designed for clinical-scale production. The platform executed all steps, from post-thaw HSPC inoculation through Cas9 electroporation, AAV6 transduction, and harvest, producing gene-edited HSPCs (geHSPCs) carrying an anti-HIV antibody transgene at the CCR5 locus with high purity, preserved differentiation potential, and editing efficiencies comparable to small-scale processing. Following transplantation into mice, geHSPCs engrafted and reconstituted multiple hematopoietic lineages, demonstrating that repopulation capacity was preserved. This work shows that clinical-scale doses of geHSPCs meeting release criteria can be produced on an automated, high-throughput platform, while preserving key product attributes and in vivo function, providing a path toward scalable and cost-effective manufacturing that could broaden access to HSPC gene therapies.
Related
- Human cytomegalovirus microRNAs target the Wnt signaling protein Dishevelled 3 to promote efficient reactivation in CD34+ hematopoietic progenitor cells
- Stathmin 1 regulates mitophagy and non-proliferative cellular function in hematopoietic stem and progenitor cells
- TNFα drives platelet hyperreactivity and thromboinflammation through regulation of hematopoietic stem and progenitor cells.
- Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice
- Closed, Automated CAR-T Cell Manufacturing: from Research to Point of Care production.
BibTeX
@misc{castelli2026endtoend,
title = {{End-To-End, Fully Automated Manufacturing of Hematopoietic Stem and Progenitor Cell Therapy Via CCR5-Targeted Integration}},
author = {Jack M.P. Castelli and Nowah Afangbedji and Sofia E. Luna and Freja K. Ekman and Dmitry Malkov and Karthik Shastry and Victor Rocha and Arpit Batish and Anna Sahakyan and Julie Fang and Zhou Li and Kayla Ruggiero and Jessica Fioravanti and Fabrizia Urbinati and Matthew H. Porteus},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.28.758978},
url = {https://www.biorxiv.org/content/10.64898/2026.10.28.758978v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - End-To-End, Fully Automated Manufacturing of Hematopoietic Stem and Progenitor Cell Therapy Via CCR5-Targeted Integration
AU - Jack M.P. Castelli
AU - Nowah Afangbedji
AU - Sofia E. Luna
AU - Freja K. Ekman
AU - Dmitry Malkov
AU - Karthik Shastry
AU - Victor Rocha
AU - Arpit Batish
AU - Anna Sahakyan
AU - Julie Fang
AU - Zhou Li
AU - Kayla Ruggiero
AU - Jessica Fioravanti
AU - Fabrizia Urbinati
AU - Matthew H. Porteus
PY - 2026
DA - 2026/10/28
PB - bioRxiv
DO - 10.64898/2026.10.28.758978
UR - https://www.biorxiv.org/content/10.64898/2026.10.28.758978v1
AB - Gene therapies utilizing hematopoietic stem and progenitor cells (HSPCs) have curative potential across hematologic diseases, but manual manufacturing workflows are costly and difficult to scale, limiting patient access. Here, we demonstrated automation of an HSPC gene knock-in protocol on a high-throughput manufacturing platform designed for clinical-scale production. The platform executed all steps, from post-thaw HSPC inoculation through Cas9 electroporation, AAV6 transduction, and harvest, producing gene-edited HSPCs (geHSPCs) carrying an anti-HIV antibody transgene at the CCR5 locus with high purity, preserved differentiation potential, and editing efficiencies comparable to small-scale processing. Following transplantation into mice, geHSPCs engrafted and reconstituted multiple hematopoietic lineages, demonstrating that repopulation capacity was preserved. This work shows that clinical-scale doses of geHSPCs meeting release criteria can be produced on an automated, high-throughput platform, while preserving key product attributes and in vivo function, providing a path toward scalable and cost-effective manufacturing that could broaden access to HSPC gene therapies.
SN - 2692-8205
ER -